Acurx Pharmaceuticals, Inc.
ACXPNASDAQHealthcare● Active
$1.62
$-0.06(-3.57%)
Market Cap$2567664
P/E Ratio—
52W High$21
52W Low$1.326
Acurx Pharmaceuticals, Inc. (ACXP) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ACXP · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 12, 2026EPS Actual
-$0.62
Est. -$0.59 · -5.1%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 12, 2026
After Market Close
▼ Miss EPS
ACXP reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.09
Rev. $41.31B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.09
Rev. Est.$41.31B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 10, 2026 | -$0.42 | — | — | — | — | — |
| ▼ Q2 FY2026 | May 12, 2026 | -$0.59 | -$0.62 | -5.1% | — | — | — |
| ▲ Q1 FY2026 | Mar 13, 2026 | -$1.01 | -$0.31 | +69.3% | — | — | — |
| ▲ Q4 FY2025 | Nov 12, 2025 | -$1.61 | -$1.23 | +23.6% | — | — | — |
| ▲ Q3 FY2025 | Aug 11, 2025 | -$2.00 | -$1.89 | +5.5% | — | — | — |
| ▼ Q2 FY2025 | May 12, 2025 | -$0.15 | -$2.20 | -1366.7% | — | — | — |
| ▲ Q1 FY2025 | Mar 17, 2025 | -$0.18 | -$0.16 | +11.1% | — | — | — |
| ▲ Q4 FY2024 | Nov 12, 2024 | -$0.23 | -$0.17 | +26.1% | — | — | — |
Q3 FY2026
Aug 10, 2026
EPS Actual
—
EPS Est.
-$0.42
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 12, 2026Miss
EPS Actual
-$0.62
EPS Est.
-$0.59
EPS Surpr.
-5.1%
Revenue
—
Q1 FY2026
Mar 13, 2026Beat
EPS Actual
-$0.31
EPS Est.
-$1.01
EPS Surpr.
+69.3%
Revenue
—
Q4 FY2025
Nov 12, 2025Beat
EPS Actual
-$1.23
EPS Est.
-$1.61
EPS Surpr.
+23.6%
Revenue
—
Q3 FY2025
Aug 11, 2025Beat
EPS Actual
-$1.89
EPS Est.
-$2.00
EPS Surpr.
+5.5%
Revenue
—
Q2 FY2025
May 12, 2025Miss
EPS Actual
-$2.20
EPS Est.
-$0.15
EPS Surpr.
-1366.7%
Revenue
—
Q1 FY2025
Mar 17, 2025Beat
EPS Actual
-$0.16
EPS Est.
-$0.18
EPS Surpr.
+11.1%
Revenue
—
Q4 FY2024
Nov 12, 2024Beat
EPS Actual
-$0.17
EPS Est.
-$0.23
EPS Surpr.
+26.1%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $-0.48 | $-0.48 | $-0.48 | 1 |
| Q3 FY2026 | $-0.37 | $-0.37 | $-0.37 | 1 |
| Q2 FY2026 | $-0.38 | $-0.38 | $-0.38 | 1 |
| Q1 FY2026 | $-1.20 | $-1.20 | $-1.20 | 1 |
| Q4 FY2025 | $-1.01 | $-1.01 | $-1.01 | 1 |
| Q3 FY2025 | $-1.31 | $-1.31 | $-1.31 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 12, 2026 | -5.1% | $2.18 | $2.05 | -5.96% |
| ▲ Q1 FY2026 | Mar 13, 2026 | +69.3% | $5.01 | $3.88 | -22.55% |
| ▲ Q4 FY2025 | Nov 12, 2025 | +23.6% | $5.58 | $4.98 | -10.75% |
| ▲ Q3 FY2025 | Aug 11, 2025 | +5.5% | $4.47 | $4.48 | +0.22% |
| ▼ Q2 FY2025 | May 12, 2025 | -1366.7% | $7.20 | $7.91 | +9.86% |
| ▲ Q1 FY2025 | Mar 17, 2025 | +11.1% | $9.22 | $9.46 | +2.60% |
| ▲ Q4 FY2024 | Nov 12, 2024 | +26.1% | $36.80 | $37.00 | +0.54% |
| ▲ Q3 FY2024 | Aug 9, 2024 | +7.1% | $38.00 | $37.60 | -1.05% |
Q2 FY2026-5.96%
Report Date
May 12, 2026
EPS Beat/Miss
-5.1%
Price Before
$2.18
Price After
$2.05
Q1 FY2026-22.55%
Report Date
Mar 13, 2026
EPS Beat/Miss
+69.3%
Price Before
$5.01
Price After
$3.88
Q4 FY2025-10.75%
Report Date
Nov 12, 2025
EPS Beat/Miss
+23.6%
Price Before
$5.58
Price After
$4.98
Q3 FY2025+0.22%
Report Date
Aug 11, 2025
EPS Beat/Miss
+5.5%
Price Before
$4.47
Price After
$4.48
Q2 FY2025+9.86%
Report Date
May 12, 2025
EPS Beat/Miss
-1366.7%
Price Before
$7.20
Price After
$7.91
Q1 FY2025+2.60%
Report Date
Mar 17, 2025
EPS Beat/Miss
+11.1%
Price Before
$9.22
Price After
$9.46
Q4 FY2024+0.54%
Report Date
Nov 12, 2024
EPS Beat/Miss
+26.1%
Price Before
$36.80
Price After
$37.00
Q3 FY2024-1.05%
Report Date
Aug 9, 2024
EPS Beat/Miss
+7.1%
Price Before
$38.00
Price After
$37.60
Avg Beat Reaction-5.17%
Avg Miss Reaction+1.95%
Beat Rate6 / 8 quarters
Largest Move-22.55% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ACXP ends December
Acurx Pharmaceuticals, Inc. (ACXP) most recently reported earnings on May 12, 2026 for Q2 FY2026, posting EPS of $-0.62 — missing the analyst consensus of $-0.59 by -5.1%. The next ACXP earnings date is expected around September 1, 2026.
Each quarter, investors track ACXP earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ACXP revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ACXP's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ACXP earnings · 5 questionsAcurx Pharmaceuticals, Inc.'s next earnings report is expected around September 1, 2026. ACXP typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ACXP historically reports after market close (AMC).
ACXP earnings datewhen is ACXP earningsACXP next earnings datewhen does ACXP report earningsACXP earnings calendar
▸ Source: FMP · Acurx Pharmaceuticals, Inc. SEC filings · US GAAP · Acurx Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026